Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India—A VRSI survey
Indian Journal of Ophthalmology · 2025
DOI: 10.4103/ijo.ijo_927_25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Manavi D Sindal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Disease Management, Polypoidal Choroidal Vasculopathy, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To present results from the Vitreo Retina Society–India (VRSI) 2024 Preference and Trends Survey, focusing on polypoidal choroidal vasculopathy (PCV) and diabetic retinopathy (DR) management practices among Indian vitreoretinal surgeons.
Methods
Responses to a 62-item questionnaire, distributed to all VRSI members over email via Google Forms, were collected over 6 weeks in July-–August 2024. Data were analyzed using descriptive statistics.
Results
A total of 289 members participated in the survey. The majority of respondents preferred multimodal imaging for the diagnosis of PCV (44.68%) and aflibercept for initiation of therapy (63.12%). Respondents preferred a loading dose with a pro-re-nata regimen (46.45%) and a switch after three injections in cases of suboptimal response (57.45%), with a strong preference for switching to brolucizumab (63.93%). Pan-retinal photocoagulation was the predominantly preferred treatment modality for all cases of proliferative DR, with an increased preference for combining it with antivascular endothelial growth factor (anti-VEGF) in cases with high-risk characteristics. For centre-involving diabetic macular edema, ranibizumab biosimilars (40.79%) in a by pro re nata regimen (53.21%) were preferred. Respondents would switch to steroids (54.48%) for suboptimal response after three anti-VEGF injections (91.04%).
Conclusions
The current preferences in the management of PCV and DR among Indian vitreoretinal surgeons are reported here. The results of this survey will assist fellow practitioners in understanding contemporary real-world practices in relation to established literature and in developing appropriate guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India.
- Smt Kanuri Santhamma Center for Vitreoretinal Diseases, Anant Bajaj Retina Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.
- Vitreoretinal and Ocular Oncology Services, Sankara Eye Hospitals, Sankara Eye Hospital, Bengaluru, Karnataka, India.
- Vitreoretinal and Oncology Services, Sankara Eye Hospitals, Sankara Eye Hospital, Bengaluru, Karnataka, India.
Zitieren
APA
Sindal, M. D., Mahendrakar, P., Kothari, A., Tyagi, M., Mishra, D., Tagare, S., Vaidya, M., & Shanmugam, M. (2025). Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India—A VRSI survey. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_927_25
Vancouver
Sindal MD, Mahendrakar P, Kothari A, Tyagi M, Mishra D, Tagare S, et al. Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India—A VRSI survey. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_927_25
BibTeX
@article{Sindal2025,
author = {Sindal, Manavi D and Mahendrakar, Priyanka and Kothari, Akshat and Tyagi, Mudit and Mishra, Divyansh and Tagare, Shivraj and Vaidya, Mihir and Shanmugam, Mahesh},
title = {Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India—A VRSI survey},
journal = {Indian Journal of Ophthalmology},
year = {2025},
doi = {10.4103/ijo.ijo_927_25}
}
EUVIMED